Cross-institution positioning
Aug 6, 2026Accumulation leaning. 1 accumulating across 1 comparable institution.
Source: Schedule 13 researchNewAmsterdam Pharma Co N.V.
Latest stored close $21.58 as of Oct 9, 2026 View live quote ↗
See how each tracked institution's reported ownership changed across SEC position dates. Full history is available with Investor or Pro access.
What the evidence shows across the newest institutional, insider, company-event, 13F, fundamental, and price data; STOCKNODE combines these layers into a quantitative research signal while preserving each source and reporting window.
Accumulation leaning. 1 accumulating across 1 comparable institution.
Source: Schedule 13 research2 increased/new, 0 reduced/exited across 2 managers in the latest comparable Form 13F quarter.
Source: Form 13F quarter-end holdingsOver the last 90 days, SEC-coded non-derivative P/S activity includes 1 purchase by 1 reporting owner and 6 sales by 3 reporting owners. Amendments are shown in the filing evidence but excluded from rolling activity totals.
Source: SEC Forms 3/4/56 non-amendment material events in the last 90 days; Latest classified evidence: Other event. Registration and prospectus filings are treated as financing capacity/disclosure evidence, not proof that securities were sold.
Source: SEC 8-K / securities filing metadataRevenue -80.7% YoY; Net income -269.4% YoY. Periods are compared only when the SEC facts are aligned and comparable.
Source: SEC Company FactsRecent close is 0% through its reported 52-week range; -12.3% over one year.
Source: Stored historical price seriesFiled Aug 6, 2026. Unlock the dated position comparison, disclosure classification, confidence, price context, and filing-specific significance analysis.
Premium research values are withheld until unlocked.
The research summary above gives the current read. This section shows the dated holder-level evidence behind it.
See each institution's newest reported position against its own prior report, with position as-of date separated from SEC filed date. Institution names and filing freshness remain public below.
Comparable holder direction grouped by SEC position as-of date — never presented as trade dates.
Compare each institution only with its own prior reported position. Public visitors can see who is tracked and how fresh the filing is; paid research reveals the actual comparison.
Investor and Pro reveal holder-by-holder changes, reported ownership history, dated breadth, disclosure timing, institution comparison, and filing-specific analysis without treating Schedule 13 reports as trade dates.
Reported Section 16 ownership activity. Rolling purchase/sale totals use non-derivative SEC transaction codes P and S only; amendments remain visible but are excluded from those totals.
| Date | Reporting owner | Code | Security | Shares | Price | Ownership | Filed |
|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | Kastelein Johannes Jacob Pieter | MExercise or conversion of derivative · derivative | Option (right to buy) | 50.2K | $0.00 | Indirect | Oct 2, 2026 |
| Sep 30, 2026 | Kastelein Johannes Jacob Pieter | SOpen-market or private sale | Ordinary Shares | 50.2K | $25.03 | Indirect | Oct 2, 2026 |
| Sep 30, 2026 | Kastelein Johannes Jacob Pieter | MExercise or conversion of derivative | Ordinary Shares | 50.2K | — | Indirect | Oct 2, 2026 |
| Sep 14, 2026 | Davidson Michael H. | POpen-market or private purchase | Ordinary Shares | 10.0K | $22.65 | Direct | Sep 15, 2026 |
| Sep 4, 2026 | Smither John W | SOpen-market or private sale | Ordinary Shares | 1.6K | $25.32 | Direct | Sep 9, 2026 |
| Sep 1, 2026 | Gunning Robert William | AGrant, award, or other acquisition · derivative | Option (right to buy) | 14.0K | $0.00 | Direct | Sep 3, 2026 |
| Sep 1, 2026 | Gunning Robert William | AGrant, award, or other acquisition | Ordinary Shares | 3.2K | $0.00 | Direct | Sep 3, 2026 |
| Aug 24, 2026 | Kastelein Johannes Jacob Pieter | MExercise or conversion of derivative · derivative | Option (right to buy) | 125.0K | $0.00 | Indirect | Aug 25, 2026 |
| Aug 24, 2026 | Kastelein Johannes Jacob Pieter | SOpen-market or private sale | Ordinary Shares | 125.0K | $26.91 | Indirect | Aug 25, 2026 |
| Aug 24, 2026 | Kastelein Johannes Jacob Pieter | MExercise or conversion of derivative | Ordinary Shares | 125.0K | — | Indirect | Aug 25, 2026 |
| Jul 20, 2026 | Kooij Louise Frederika | MExercise or conversion of derivative · derivative | Option (right to buy) | 80.0K | $0.00 | Direct | Jul 22, 2026 |
| Jul 20, 2026 | Kooij Louise Frederika | MExercise or conversion of derivative · derivative | Option (right to buy) | 25.0K | $0.00 | Direct | Jul 22, 2026 |
| Jul 20, 2026 | Kooij Louise Frederika | SOpen-market or private sale | Ordinary Shares | 2.9K | $31.71 | Direct | Jul 22, 2026 |
| Jul 20, 2026 | Kooij Louise Frederika | SOpen-market or private sale | Ordinary Shares | 31.9K | $31.05 | Direct | Jul 22, 2026 |
| Jul 20, 2026 | Kooij Louise Frederika | SOpen-market or private sale | Ordinary Shares | 70.2K | $29.96 | Direct | Jul 22, 2026 |
| Jul 20, 2026 | Kooij Louise Frederika | MExercise or conversion of derivative | Ordinary Shares | 80.0K | $11.17 | Direct | Jul 22, 2026 |
| Jul 20, 2026 | Kooij Louise Frederika | MExercise or conversion of derivative | Ordinary Shares | 25.0K | $11.90 | Direct | Jul 22, 2026 |
| Jun 22, 2026 | Kooij Louise Frederika | MExercise or conversion of derivative · derivative | Option (right to buy) | 15.0K | $0.00 | Direct | Jun 24, 2026 |
| Jun 22, 2026 | Kooij Louise Frederika | MExercise or conversion of derivative · derivative | Option (right to buy) | 25.0K | $0.00 | Direct | Jun 24, 2026 |
| Jun 22, 2026 | Kooij Louise Frederika | SOpen-market or private sale | Ordinary Shares | 300 | $30.73 | Direct | Jun 24, 2026 |
Recent 8-K item classifications plus securities registration and prospectus filings. Registration or prospectus filings show financing capacity/disclosure activity; they do not by themselves prove that securities were sold.
| Filed | Form | 8-K item(s) | Classification | Capital context | SEC |
|---|---|---|---|---|---|
| Sep 29, 2026 | 8-K | 8.01, 9.01 | Other event; Financial statements / exhibits | — | Filing |
| Sep 21, 2026 | 8-K | 8.01 | Other event | — | Filing |
| Aug 14, 2026 | 8-K/AAmendment | 5.02 | Director or executive change | — | Filing |
| Aug 14, 2026 | 8-K | 5.02 | Director or executive change | — | Filing |
| Aug 5, 2026 | 8-K | 2.02, 9.01 | Results of operations / financial condition; Financial statements / exhibits | — | Filing |
| Jul 24, 2026 | 8-K | 8.01, 9.01 | Other event; Financial statements / exhibits | — | Filing |
| Jul 22, 2026 | 8-K | 5.02 | Director or executive change | — | Filing |
| Jun 5, 2026 | S-8 | — | Employee-plan securities registration | Equity | Filing |
| Jun 3, 2026 | 8-K | 5.02, 5.07, 9.01 | Director or executive change; Shareholder vote results; Financial statements / exhibits | — | Filing |
| May 7, 2026 | 8-K | 2.02, 9.01 | Results of operations / financial condition; Financial statements / exhibits | — | Filing |
| Apr 24, 2026 | 8-K | 5.02 | Director or executive change | — | Filing |
| Mar 2, 2026 | 8-K | 7.01, 9.01 | Regulation FD disclosure; Financial statements / exhibits | — | Filing |
Period-aligned SEC facts. Comparisons appear only when periods and units are comparable.
| Period | Revenue | YoY |
|---|---|---|
| Ended Jun 30, 2026 | $3.7M | -80.7% |
| Ended Mar 31, 2026 | $3.0M | +2.1% |
| Ended Sep 30, 2025 | $348.0K | -98.8% |
| Ended Jun 30, 2025 | $19.1M | +740.1% |
| Period | Revenue | YoY |
|---|---|---|
| Ended Dec 31, 2025 | $22.5M | -50.6% |
| Ended Dec 31, 2024 | $45.6M | +223.4% |
| Ended Dec 31, 2023 | $14.1M | -86.3% |
| Ended Dec 31, 2022 | $102.7M | — |
Dated price context from the historical market series already collected for this security.
Returns are close-to-close price changes. Volatility and drawdown are factual historical context, not recommendations.
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred from changes in reported shares when available; it is not a list of individual trades or exact execution prices.
Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
For more context, see how to read a Schedule 13G, filing date vs event date, or Schedule 13G vs Schedule 13D.
| Holder | Observed / filed | Reported change | Shares | Ownership | Observation | Filing | Latest |
|---|---|---|---|---|---|---|---|
| Fidelity / FMR CIK0000315066 | Jun 30, 2026 observed Aug 6, 2026 filed · 37d Schedule 13G amendment | Reported accumulation | 10.3M +1.6M | 8.80% -3.20 pts | $33.89 | $27.67 | $21.58 |
| Fidelity / FMR CIK0000315066 | Mar 31, 2026 observed May 6, 2026 filed · 36d Schedule 13G amendment | Reported accumulation | 8.8M +2.4M | 12.00% 0.00 pts | $32.01 | $30.99 | $21.58 |
| Fidelity / FMR CIK0000315066 | Dec 31, 2025 observed Feb 5, 2026 filed · 36d Initial Schedule 13G | Initial Schedule 13G | 6.4M | 12.00% | $35.08 | $32.06 | $21.58 |
Compare NAMS with other securities showing similar institutional activity or recent accumulation across several tracked institutions.